BioCentury | Mar 25, 2021
Product Development

CEOs, VCs split on blame for DSMB debacle, aligned on AZ vaccine efficacy

The fallout from AstraZeneca’s public clash with the DSMB of its U.S. Phase III trial will hurt the company individually more than biopharma as a whole. But the incident chips away at the broad goodwill...
BioCentury | Mar 12, 2021
Product Development

Vir’s mAb on par with Lilly combo in early stage patients

Vir’s COVID mAb has produced some of the strongest data to date in high-risk outpatients, reducing hospitalization or death by 85% (p=0.002). Vir Biotechnology Inc. (NASDAQ:VIR) and partner GlaxoSmithKline...
BioCentury | Feb 6, 2021
Product Development

AstraZeneca’s vaccine results suggest a modality-independent dip in protection against variants

AstraZeneca is the latest company to report that its COVID-19 vaccine seems to be working against new variants of the virus, just not quite as well. So far, that effect has been independent of the...
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase I data for VXA-CoV2-1. The data showed the vaccine did evoke CD8+ T cell and IgA responses but no detectable serum neutralizing antibodies....
BioCentury | Feb 3, 2021
Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has efficacy on par with other leading vaccines across several groups: the full population, those who had not yet received a second dose, and the...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Dec 17, 2020
Product Development

Two non-amyloid therapies for Alzheimer’s advance to late-stage trials

December has been a busy month for Alzheimer’s therapies testing new hypotheses outside of amyloid, with the latest coming Wednesday from Novo Nordisk, which said it is taking semaglutide into Phase III...
BioCentury | Nov 25, 2020
Product Development

Steady stream of Phase III COVID-19 vaccine data to flow into the new year

The dizzying pace of COVID-19 vaccine readouts over the last three weeks is only going to accelerate over the next five. By the end of the year, three of the four leading vaccines are likely...
BioCentury | Oct 23, 2020

SPAC to the future: an old-time IPO alternative may be back to stay

Investors and bankers believe specialist-backed SPACs could become a cyclical part of biotech’s fund-raising equation with some clear advantages over traditional IPOs for the right type of company. But...
BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

CRISPR Therapeutics’ first allogeneic CAR T therapy readout supports the idea that the therapeutic class can yield efficacy on par with autologous CAR Ts, without causing graft-versus-host disease. But a patient death raises the possibility allogeneic...
Items per page:
1 - 10 of 692